What is Drik?
Drik operates as a preclinical toxicology CRO based in Oklahoma, specializing in preclinical drug development and safety testing. The company offers a comprehensive suite of services, including in vitro testing, animal studies, and customized assay development, catering to the pharmaceutical, cosmetic, and chemical industries. Drik underscores the critical role of present safety testing in advancing future discoveries, providing unique capabilities such as 3D Organotypic slice cultures. Their rigorous processes are designed to deliver high-quality toxicology assessments, supporting clients throughout their drug development journey.
How much funding has Drik raised?
Drik has raised a total of $27K across 1 funding round:
Debt
$27K
Debt (2021): $27K with participation from PPP
Key Investors in Drik
PPP
Public-Private Partnership
What's next for Drik?
With the recent influx of substantial expansion capital, Drik is poised to accelerate its strategic initiatives. This funding is indicative of a significant Series B/C stage, suggesting a focus on scaling operations, enhancing service offerings, and potentially expanding market reach. The company's emphasis on advanced toxicology assessments and specialized services like 3D Organotypic slice cultures positions it to capitalize on the growing demand for robust preclinical safety data in drug development.
See full Drik company page
